MININEPH™ and MININEPH™PLUS

This kit is designed for the measurement of ß2M in human serum and urine. The kit includes latex enhanced ß2M reagent, buffer, calibrator and controls sufficient for a minimum of 150 tests

A ß2 Microglobulin assay is also available on the SPAplus analyser

BN™II is a trademark of Siemens Healthcare Diagnostics Inc.
 

This kit is designed for the measurement of human RBP in urine. The kit includes latex enhanced RBP reagent, buffer, calibrator and control, sufficient for 100 tests.

*For research use only.

When a small blood vessel is injured, a series of reactions is initiated leading to the formation of a blood clot. This seals the vessel preventing further blood loss. Many of the clotting factors involved are enzymes which are activated during this cascade of events. There are three parts of the coagulation cascade; the intrinsic pathway, the extrinsic pathway and the common pathway. The end product of both the intrinsic, and the faster extrinsic pathway, is activated Factor X. This factor initiates a further cascade through the common pathway resulting in the formation of a stable fibrin clot at the site of injury.

Key factors in the clotting mechanism can be measured by Binding Site RID kits. These include Fibrinogen and Factor XIII, as well as protease inhibitors and anticoagulants that localise and limit the clotting process, for example anti-thrombin III (ATIII) and Protein C.

 # Diluted sample applied - assay range may be extended using undiluted sample.
* Research use only
 

Radial immunodiffusion RID kits are available for laboratory detection of many other commonly measured human proteins e.g. albumin.

# Diluted sample applied - assay range may be extended using undiluted sample.
* Research use only

Click here for animal RID kits

SPE gel – Tracks. 1 & 10 Normal Serum. 2, 3, 4 IgG paraproteins. 5, 6, 7 IgA paraproteins. 8,9 IgM paraproteins

Serum protein electrophoresis (SPE or SPEP) can be used for the initial screening of serum (or concentrated urine) for monoclonal immunoglobulins or M-protein and light chains (Bence Jones protein), aiding in the diagnosis of monoclonal gammopathies.

However, optimal detection of paraproteins is achieved by screening serum samples both with SPE or CZE (Capillary Zone Electrophoresis) and Freelite® serum free light chain assays.

Samples exhibiting either abnormal bands by SPE or abnormal levels of free kappa, free lambda or κ/λ ratio by Freelite® should be further investigated by immunofixation and quantitation of other specific serum proteins.

Each SPE kit contains reagents sufficient for 100 tests. Each of the 10 gels can be used to run 10 samples.

IgM Lambda and IgG Kappa monoclonal immunoglobulins on a MINIFIX IFE gel

Immunofixation electrophoresis (IFE) is a two-stage process combining agarose gel electrophoresis with immuno-precipitation. It has replaced IEP (immunoelectrophoresis) as the method of choice for identification and characterisation of monoclonal immunoglobulins in serum, urine and cerebrospinal fluid. IFE allows ease of interpretation, fast results (less than 2 hours) and has good sensitivity.

Standard IFE

• One patient sample per gel (102 x 77mm)

• Six gel tracks (IgG, IgM, IgA, Kappa, Lambda, Total Serum Protein)

MINIFIX™ IFE

• Two Patient samples per gel (102x77mm)

• 2x six gel tracks (IgG, IgM, IgA, Kappa, Lambda, Total Serum Protein)

IFE Components

Individual vials of immunofixation antisera are available for customers who prefer to purchase reagents separately. These products are optimised for use with the IFE (XK002) gel kit which contains the same components as a standard IFE kit but without antisera.

MININEPH™™, Freelite®, Nanorid™™, SPAplus™ and MINIFIX™ are trademarks of The Binding Site Group Ltd, Birmingham, UK.
BN™II is a trademark of Siemens Healthcare Diagnostics Inc.

1. Flodin, M. et al. Variations in assay protocol for the Dako Cystatin C method may change patient results by 50% without changing the results for controls. Clinical Chemistry and Laboratory Medicine 2006; 44: 1481-1485

2. Mojiminiyi, O.A. et al. (2003). Evaluation of Cystatin C and β-2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications 2003; 17: 160-168